Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 40

1.

Compliance and Effectiveness of Smoking Cessation Program Started on Hospitalized Patients.

Shin GH, Yi SW, Cheong YS, Park EW, Choi EY.

Korean J Fam Med. 2016 May;37(3):149-55. doi: 10.4082/kjfm.2016.37.3.149. Epub 2016 May 26.

2.

Varenicline in smokers with diabetes: A pooled analysis of 15 randomized, placebo-controlled studies of varenicline.

Tonstad S, Lawrence D.

J Diabetes Investig. 2017 Jan;8(1):93-100. doi: 10.1111/jdi.12543. Epub 2016 Jul 14.

3.

Varenicline and Adverse Cardiovascular Events: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Sterling LH, Windle SB, Filion KB, Touma L, Eisenberg MJ.

J Am Heart Assoc. 2016 Feb 22;5(2). pii: e002849. doi: 10.1161/JAHA.115.002849. Review.

4.

Effectiveness of varenicline and counselling for smoking cessation in an observational cohort study in China.

Jiang B, He Y, Zuo F, Wu L, Liu QH, Zhang L, Zhou CX, Cheng KK, Chan SS, Lam TH.

BMJ Open. 2016 Jan 6;6(1):e009381. doi: 10.1136/bmjopen-2015-009381.

5.

Evaluation of the cardiovascular effects of varenicline in rats.

Selçuk EB, Sungu M, Parlakpinar H, Ermiş N, Taslıdere E, Vardı N, Yalçınsoy M, Sagır M, Polat A, Karatas M, Kayhan-Tetik B.

Drug Des Devel Ther. 2015 Oct 22;9:5705-17. doi: 10.2147/DDDT.S92268. eCollection 2015.

6.

Smoking cessation in Asians: focus on varenicline.

Xiao D, Chu S, Wang C.

Patient Prefer Adherence. 2015 Apr 13;9:579-84. doi: 10.2147/PPA.S60785. eCollection 2015. Review. Erratum in: Patient Prefer Adherence. 2015;9:1075.

7.

Seven-day continuous abstinence rate from smoking at 1, 2, or 3 years after the use of varenicline.

Kim JS, Jang JY, Park EH, Lee JY, Gu KM, Jung JW, Choi JC, Shin JW, Park IW, Choi BW, Kim JY.

Tuberc Respir Dis (Seoul). 2015 Apr;78(2):92-8. doi: 10.4046/trd.2015.78.2.92. Epub 2015 Apr 2.

8.

Risk of neuropsychiatric adverse events associated with varenicline: systematic review and meta-analysis.

Thomas KH, Martin RM, Knipe DW, Higgins JP, Gunnell D.

BMJ. 2015 Mar 12;350:h1109. doi: 10.1136/bmj.h1109. Review.

9.

Effectiveness of smoking cessation using motivational interviewing in patients consulting a pulmonologist.

Lim G, Park I, Park S, Song S, Kim H, Kim S.

Tuberc Respir Dis (Seoul). 2014 Jun;76(6):276-83. doi: 10.4046/trd.2014.76.6.276. Epub 2014 Jun 28.

10.

Retreatment with varenicline for smoking cessation in smokers who have previously taken varenicline: a randomized, placebo-controlled trial.

Gonzales D, Hajek P, Pliamm L, Nackaerts K, Tseng LJ, McRae TD, Treadow J.

Clin Pharmacol Ther. 2014 Sep;96(3):390-6. doi: 10.1038/clpt.2014.124. Epub 2014 Jun 9.

11.

Varenicline for smoking cessation: A review of the literature.

Kaur K, Kaushal S, Chopra SC.

Curr Ther Res Clin Exp. 2009 Feb;70(1):35-54. doi: 10.1016/j.curtheres.2009.02.004. Erratum in: Curr Ther Res Clin Exp. 2010;71(1):89.

12.

Cardiovascular events associated with smoking cessation pharmacotherapies: a network meta-analysis.

Mills EJ, Thorlund K, Eapen S, Wu P, Prochaska JJ.

Circulation. 2014 Jan 7;129(1):28-41. doi: 10.1161/CIRCULATIONAHA.113.003961. Epub 2013 Dec 9.

13.

Adherence to varenicline and abstinence rates for quitting smoking in a private health promotion center-based smoking cessation clinic.

Lee JY, Kim MJ, Jun HJ, Kang M, Park AR, Oh DE, Choi YH, Hwang JH.

Tuberc Respir Dis (Seoul). 2012 May;72(5):426-32. doi: 10.4046/trd.2012.72.5.426. Epub 2012 May 29.

14.

Varenicline for Smoking Cessation in Schizophrenia: Safety and Effectiveness in a 12-Week, Open-Label Trial.

Pachas GN, Cather C, Pratt SA, Hoeppner B, Nino J, Carlini SV, Achtyes ED, Lando H, Mueser KT, Rigotti NA, Goff DC, Evins AE.

J Dual Diagn. 2012;8(2):117-125. Epub 2012 May 11.

15.

Weight gain in smokers after quitting cigarettes: meta-analysis.

Aubin HJ, Farley A, Lycett D, Lahmek P, Aveyard P.

BMJ. 2012 Jul 10;345:e4439. doi: 10.1136/bmj.e4439.

16.
17.

A single administration of low-dose varenicline saturates α4β2* nicotinic acetylcholine receptors in the human brain.

Lotfipour S, Mandelkern M, Alvarez-Estrada M, Brody AL.

Neuropsychopharmacology. 2012 Jun;37(7):1738-48. doi: 10.1038/npp.2012.20. Epub 2012 Mar 7.

18.

A randomized placebo-controlled trial of varenicline for smoking cessation allowing flexible quit dates.

Rennard S, Hughes J, Cinciripini PM, Kralikova E, Raupach T, Arteaga C, St Aubin LB, Russ C; Flexible Quit Date Study Group.

Nicotine Tob Res. 2012 Mar;14(3):343-50. doi: 10.1093/ntr/ntr220. Epub 2011 Nov 11.

19.

Safety and tolerability of varenicline tartrate (Champix(®)/Chantix(®)) for smoking cessation in HIV-infected subjects: a pilot open-label study.

Cui Q, Robinson L, Elston D, Smaill F, Cohen J, Quan C, McFarland N, Thabane L, McIvor A, Zeidler J, Smieja M.

AIDS Patient Care STDS. 2012 Jan;26(1):12-9. doi: 10.1089/apc.2011.0199. Epub 2011 Oct 18.

20.

Unannounced telephone pill counts for assessing varenicline adherence in a pilot clinical trial.

Thompson N, Nazir N, Cox LS, Faseru B, Goggin K, Ahluwalia JS, Nollen NL.

Patient Prefer Adherence. 2011;5:475-82. doi: 10.2147/PPA.S24023. Epub 2011 Sep 28.

Supplemental Content

Support Center